OPPM
Opus Point Partners Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | $1.1M | Buy |
13,684
+333
| +2% | +$26.8K | 1.99% | 9 |
|
|
2019
Q2 | $969K | Hold |
13,351
| – | – | 1.43% | 15 |
|
|
2019
Q1 | $1.25M | Sell |
13,351
-904
| -6% | -$84.5K | 1.69% | 11 |
|
|
2018
Q4 | $1.04M | Buy |
14,255
+756
| +6% | +$55.1K | 2.29% | 10 |
|
|
2018
Q3 | $1.18M | Sell |
13,499
-613
| -4% | -$53.6K | 2.82% | 12 |
|
|
2018
Q2 | $1.39M | Buy |
14,112
+432
| +3% | +$42.6K | 3.01% | 9 |
|
|
2018
Q1 | $1.63M | Sell |
13,680
-29,384
| -68% | -$3.5M | 3.2% | 6 |
|
|
2017
Q4 | $5.47M | Sell |
43,064
-4,395
| -9% | -$558K | 4.73% | 5 |
|
|
2017
Q3 | $5.58M | Sell |
47,459
-1,636
| -3% | -$192K | 5% | 4 |
|
|
2017
Q2 | $3.92M | Sell |
49,095
-41,026
| -46% | -$3.27M | 3.59% | 6 |
|
|
2017
Q1 | $4.62M | Buy |
90,121
+1,337
| +2% | +$68.5K | 3.43% | 7 |
|
|
2016
Q4 | $3.32M | Buy |
88,784
+43,720
| +97% | +$1.64M | 2.65% | 11 |
|
|
2016
Q3 | $3.05M | Buy |
45,064
+1,380
| +3% | +$93.5K | 1.71% | 14 |
|
|
2016
Q2 | $2.42M | Sell |
43,684
-33,909
| -44% | -$1.88M | 2.34% | 18 |
|
|
2016
Q1 | $4.87M | Buy |
77,593
+27,371
| +55% | +$1.72M | 3.77% | 3 |
|
|
2015
Q4 | $4.73M | Buy |
50,222
+1,774
| +4% | +$167K | 3.12% | 14 |
|
|
2015
Q3 | $3.89M | Buy |
48,448
+13,469
| +39% | +$1.08M | 2.15% | 21 |
|
|
2015
Q2 | $4.19M | Sell |
34,979
-2,409
| -6% | -$289K | 3.32% | 14 |
|
|
2015
Q1 | $3.9M | Buy |
37,388
+19,513
| +109% | +$2.04M | 3.27% | 10 |
|
|
2014
Q4 | $1.73M | Buy |
+17,875
| New | +$1.73M | 1.72% | 25 |
|